CONCORD MANUFACTURING LIBERTY SELECT CYCLER ASSY(NON-VALUATED); SYSTEM, PERITONEAL, AUTOMATIC DELIVERY
|
Back to Search Results |
|
Model Number 180343 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Inflammation (1932); Peritonitis (2252)
|
Event Date 02/22/2022 |
Event Type
Injury
|
Manufacturer Narrative
|
The plant investigation is in process.A supplemental mdr will be submitted upon completion of this activity.Clinical investigation: a temporal relationship exists between ccpd therapy utilizing the liberty select cycler with the liberty cycler set and the adverse events of peritonitis.It is well established pd patients are at high risk for infections of the peritoneum.The cause of the patient¿s peritonitis can be attributed to intra-abdominal sources as reported by a medical professional.Though a less common source of peritonitis infections, it is well known transmission of peritonitis causing pathogens can be from intra-abdominal sources, particularly in the environment of an active gi infection.Therefore, the liberty select cycler and liberty cycler set can be excluded as a root cause or contributor to this patient¿s adverse event.Based on the required information, there was no allegation or objective evidence any fresenius product(s) or device(s) deficiency or malfunction caused or contributed to this patient¿s adverse event.Should additional information become available related to any fresenius device(s) and/or product(s), please re-submit for a clinical review and the need for a clinical investigation will be reassessed accordingly.
|
|
Event Description
|
It was reported a peritoneal dialysis (pd) patient on continuous cyclic pd (ccpd) therapy on the liberty select cycler experienced bowel inflammation and presented to the emergency department (ed).There was no specific allegation this adverse event was due to a deficiency or malfunction of any fresenius product(s) or device(s) in the initial reporting.Upon follow up with the patient¿s pdrn, it was reported this patient presented to the ed and was hospitalized on (b)(6) 2022 for an undetermined gastrointestinal (gi) illness.The patient did not experience symptoms on or around the time of a pd treatment.The patient recently had a covid-19 infection and a clostridium difficile lower gi infection (dates of diagnoses unknown), both diagnoses determined to be unrelated to pd therapy or the use of any fresenius product(s) or device(s).The patient¿s pd catheter (not a fresenius product) was removed due to severity of the bowel inflammation and the patient underwent hemodialysis (hd) for renal replacement therapy on a hospital provided hd machine (unknown brand and model) for the duration of the admission.The patient was diagnosed with peritonitis due to intra-abdominal sources while hospitalized; however, peritoneal effluent fluid cultures and white blood cell (wbc) count results were not provided to the outpatient clinic.The patient was given intravenous antibiotics for multiple infections while hospitalized but the type, route, dose and frequency were not reported to the outpatient clinic.The patient is recovering from this event while awaiting discharge.It was confirmed the patient¿s unspecified gi illness, covid-19 infection, clostridium difficile gi infection and associated bowel inflammation were unrelated to pd therapy or the use of any fresenius product(s) or device(s).Additionally, it was affirmed the patient¿s peritonitis, and hospitalization were not due to a deficiency or malfunction of nay fresenius product(s) or device(s).The patient will continue hd on an in-center basis upon discharge with plans to return to pd therapy once cleared by his nephrologist.
|
|
Event Description
|
It was reported a peritoneal dialysis (pd) patient on continuous cyclic pd (ccpd) therapy on the liberty select cycler experienced bowel inflammation and presented to the emergency department (ed).There was no specific allegation this adverse event was due to a deficiency or malfunction of any fresenius product(s) or device(s) in the initial reporting.Upon follow up with the patient¿s pdrn, it was reported this patient presented to the ed and was hospitalized on (b)(6) 2022 for an undetermined gastrointestinal (gi) illness.The patient did not experience symptoms on or around the time of a pd treatment.The patient recently had a covid-19 infection and a clostridium difficile lower gi infection (dates of diagnoses unknown), both diagnoses determined to be unrelated to pd therapy or the use of any fresenius product(s) or device(s).The patient¿s pd catheter (not a fresenius product) was removed due to severity of the bowel inflammation and the patient underwent hemodialysis (hd) for renal replacement therapy on a hospital provided hd machine (unknown brand and model) for the duration of the admission.The patient was diagnosed with peritonitis due to intra-abdominal sources while hospitalized; however, peritoneal effluent fluid cultures and white blood cell (wbc) count results were not provided to the outpatient clinic.The patient was given intravenous antibiotics for multiple infections while hospitalized but the type, route, dose and frequency were not reported to the outpatient clinic.The patient is recovering from this event while awaiting discharge.It was confirmed the patient¿s unspecified gi illness, covid-19 infection, clostridium difficile gi infection and associated bowel inflammation were unrelated to pd therapy or the use of any fresenius product(s) or device(s).Additionally, it was affirmed the patient¿s peritonitis, and hospitalization were not due to a deficiency or malfunction of nay fresenius product(s) or device(s).The patient will continue hd on an in-center basis upon discharge with plans to return to pd therapy once cleared by his nephrologist.
|
|
Manufacturer Narrative
|
Plant investigation: no parts were returned to the manufacturer for physical evaluation.A records review was performed on the reported serial number.An investigation of the device manufacturing records was conducted by the manufacturer.There were no non-conformances, or any associated rework identified during the manufacturing process which could be related to the reported event.In addition, the device history record (dhr) review confirmed the results of the in-progress and final quality control (qc) testing met all requirements.The investigation into the cause of the reported problem was not able to be confirmed.A definitive conclusion regarding the complaint incident cannot be reached without a physical examination of the complaint device.
|
|
Manufacturer Narrative
|
Correction: b5.
|
|
Event Description
|
It was reported a peritoneal dialysis (pd) patient on continuous cyclic pd (ccpd) therapy on the liberty select cycler experienced bowel inflammation and presented to the emergency department (ed).There was no specific allegation this adverse event was due to a deficiency or malfunction of any fresenius product(s) or device(s) in the initial reporting.Upon follow up with the patient¿s pdrn, it was reported this patient presented to the ed and was hospitalized on 22/feb/2022 for an undetermined gastrointestinal (gi) illness.The patient did not experience symptoms on or around the time of a pd treatment.The patient recently had a covid-19 infection and a clostridium difficile lower gi infection (dates of diagnoses unknown), both diagnoses determined to be unrelated to pd therapy or the use of any fresenius product(s) or device(s).The patient¿s pd catheter (not a fresenius product) was removed due to severity of the bowel inflammation and the patient underwent hemodialysis (hd) for renal replacement therapy on a hospital provided hd machine (unknown brand and model) for the duration of the admission.The patient was diagnosed with peritonitis due to intra-abdominal sources while hospitalized; however, peritoneal effluent fluid cultures and white blood cell (wbc) count results were not provided to the outpatient clinic.The patient was given intravenous antibiotics for multiple infections while hospitalized but the type, route, dose and frequency were not reported to the outpatient clinic.The patient is recovering from this event while awaiting discharge.It was confirmed the patient¿s unspecified gi illness, covid-19 infection, clostridium difficile gi infection and associated bowel inflammation were unrelated to pd therapy or the use of any fresenius product(s) or device(s).Additionally, it was affirmed the patient¿s peritonitis, and hospitalization were not due to a deficiency or malfunction of any fresenius product(s) or device(s).The patient will continue hd on an in-center basis upon discharge with plans to return to pd therapy once cleared by his nephrologist.
|
|
Search Alerts/Recalls
|
|
|